Please login to the form below

Not currently logged in
Email:
Password:

Opsumit

This page shows the latest Opsumit news and features for those working in and with pharma, biotech and healthcare.

FDA ‘names and shames’ generic-blocking pharma companies

FDA ‘names and shames’ generic-blocking pharma companies

Pomalyst, followed by Actelion with 26 inquiries mainly for pulmonary artery hypertension drugs Tracleer and Opsumit.

Latest news

More from news
Approximately 8 fully matching, plus 10 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag). ... He also led and managed the highly successful launches of Opsumit,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics